Ost-müük Calcimedica Inc - CALC CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | 0.4142 | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024068% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.001846% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 0.001 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Võtmestatistika
| Eelmine sulgemine* | 5.5768 |
| Avatud* | 5.3405 |
| Aastane muutus* | 310.81% |
| Päeva ulatus* | 5.3405 - 5.6149 |
| 52 nädala ulatus | 4.88-20.30 |
| Keskmine maht (10 päeva) | 20.21K |
| Keskmine maht (3 kuud) | 96.67K |
| Turukapitalisatsioon | 9.23M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 1.57M |
| Tulu | N/A |
| EPS | -23.21 |
| Dividendid (% kasumist) | N/A |
| Beeta | -100.00K |
| Järgmine tuluaruande kuupäev | May 8, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|---|---|---|---|---|---|
| Mar 23, 2023 | 5.4929 | 0.1525 | 2.86% | 5.3404 | 5.8023 | 5.3404 |
| Mar 22, 2023 | 5.5768 | 0.2301 | 4.30% | 5.3467 | 6.5507 | 5.0805 |
| Mar 21, 2023 | 6.0468 | 1.2311 | 25.56% | 4.8157 | 6.1436 | 4.7284 |
| Mar 20, 2023 | 5.3451 | -0.6469 | -10.80% | 5.9920 | 5.9920 | 5.0602 |
| Mar 17, 2023 | 0.4280 | -0.0478 | -10.05% | 0.4758 | 0.4763 | 0.4273 |
| Mar 16, 2023 | 0.4761 | -0.0195 | -3.93% | 0.4956 | 0.4958 | 0.4580 |
| Mar 15, 2023 | 0.4937 | 0.0277 | 5.94% | 0.4660 | 0.4969 | 0.4660 |
| Mar 14, 2023 | 0.4762 | -0.0145 | -2.95% | 0.4907 | 0.4957 | 0.4737 |
| Mar 13, 2023 | 0.4960 | -0.0093 | -1.84% | 0.5053 | 0.5151 | 0.4859 |
| Mar 10, 2023 | 0.5041 | 0.0008 | 0.16% | 0.5033 | 0.5120 | 0.4857 |
| Mar 9, 2023 | 0.5346 | -0.0034 | -0.63% | 0.5380 | 0.5637 | 0.5164 |
| Mar 8, 2023 | 0.5638 | 0.0408 | 7.80% | 0.5230 | 0.5647 | 0.5230 |
| Mar 7, 2023 | 0.5637 | 0.0395 | 7.54% | 0.5242 | 0.5823 | 0.5242 |
| Mar 6, 2023 | 0.5556 | -0.0273 | -4.68% | 0.5829 | 0.5829 | 0.5537 |
| Mar 3, 2023 | 0.5476 | 0.0429 | 8.50% | 0.5047 | 0.5588 | 0.5047 |
| Mar 2, 2023 | 0.5345 | 0.0292 | 5.78% | 0.5053 | 0.5347 | 0.5053 |
| Mar 1, 2023 | 0.5390 | 0.0045 | 0.84% | 0.5345 | 0.5832 | 0.5339 |
| Feb 28, 2023 | 0.5285 | -0.0056 | -1.05% | 0.5341 | 0.5347 | 0.5179 |
| Feb 27, 2023 | 0.5536 | -0.0004 | -0.07% | 0.5540 | 0.5543 | 0.5343 |
| Feb 24, 2023 | 0.5439 | -0.0390 | -6.69% | 0.5829 | 0.5975 | 0.5273 |
Calcimedica Inc Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| No events scheduled | ||
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0 |
| Kogu tegevuskulu | 35.947 | 29.832 | 37.502 | 28.57 |
| Müük/Üldine/admin kulud, kokku | 17.044 | 8.87 | 6.922 | 5.599 |
| Uuringud ja arendus | 18.903 | 20.962 | 30.58 | 22.971 |
| Tulud majandustegevusest | -35.947 | -29.832 | -37.502 | -28.57 |
| Intressitulud (kulu), muud tulud, neto | 0.126 | 0.143 | 0.393 | 0.192 |
| Muud, neto | 0 | 2.158 | 0.072 | 0 |
| Netotulu enne makse | -35.821 | -27.531 | -37.037 | -28.378 |
| Netotulu pärast makse | -35.821 | -27.531 | -37.037 | -28.378 |
| Netotulu enne erikulusid | -35.821 | -27.531 | -37.037 | -28.378 |
| Netotulu | -35.821 | -27.531 | -37.037 | -28.378 |
| Total Adjustments to Net Income | 0 | -7.189 | -7.055 | -4.317 |
| Arvestatav tulu, v a erikulud | -35.821 | -34.72 | -44.092 | -32.695 |
| Arvestatav tulu, koos erikuludega | -35.821 | -34.72 | -44.092 | -32.695 |
| Jaotamisele kuuluv netotulu | -35.821 | -34.72 | -44.092 | -32.695 |
| Keskmine jaotamisele kuuluv aktsia kohta | 21.1993 | 21.044 | 19.1556 | 19.1556 |
| Jaotatav EPS, v a erakorralised kulud | -1.68973 | -1.64988 | -2.30178 | -1.70681 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
| Jaotamisele kuuluv normaal-EPS | -1.68973 | -1.64988 | -2.30178 | -1.70681 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0 | 0 |
| Kogu tegevuskulu | 10.184 | 8.701 | 8.017 | 7.741 | 11.488 |
| Müük/Üldine/admin kulud, kokku | 4.127 | 4.433 | 3.996 | 3.575 | 5.04 |
| Uuringud ja arendus | 6.057 | 4.268 | 4.021 | 4.166 | 6.448 |
| Tulud majandustegevusest | -10.184 | -8.701 | -8.017 | -7.741 | -11.488 |
| Intressitulud (kulu), muud tulud, neto | 0.035 | 0.026 | 0.028 | 0.033 | 0.039 |
| Muud, neto | 0 | 0 | 0 | 0 | |
| Netotulu enne makse | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
| Netotulu pärast makse | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
| Netotulu enne erikulusid | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
| Netotulu | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
| Total Adjustments to Net Income | 0 | 0 | 0 | 0 | |
| Arvestatav tulu, v a erikulud | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
| Arvestatav tulu, koos erikuludega | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
| Jaotamisele kuuluv netotulu | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
| Keskmine jaotamisele kuuluv aktsia kohta | 21.3578 | 21.3376 | 21.2875 | 21.1487 | 21.0204 |
| Jaotatav EPS, v a erakorralised kulud | -0.47519 | -0.40656 | -0.37529 | -0.36447 | -0.54466 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -0.47519 | -0.40656 | -0.37529 | -0.36447 | -0.54466 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Käibevarad kokku | 67.078 | 99.24 | 36.271 | 13.445 |
| Raha ja lühiajalised investeeringud | 63.67 | 95.033 | 35.956 | 12.834 |
| Raha ja ekvivalendid | 13.364 | 33.418 | 15.87 | 12.834 |
| Lühiajalised investeeringud | 50.306 | 61.615 | 20.086 | 0 |
| Prepaid Expenses | 2.034 | 4.207 | 0.315 | 0.611 |
| Total Assets | 69.088 | 101.794 | 40.66 | 17.813 |
| Property/Plant/Equipment, Total - Net | 1.981 | 1.946 | 1.975 | 1.515 |
| Property/Plant/Equipment, Total - Gross | 3.634 | 3.08 | 2.714 | 1.958 |
| Accumulated Depreciation, Total | -1.653 | -1.134 | -0.739 | -0.443 |
| Other Long Term Assets, Total | 0.029 | 0.608 | 2.414 | 2.853 |
| Total Current Liabilities | 4.057 | 6.997 | 12.251 | 5.794 |
| Accounts Payable | 0.527 | 2.513 | 4.636 | 2.523 |
| Accrued Expenses | 2.582 | 3.658 | 4.377 | 2.924 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.948 | 0.826 | 3.238 | 0.347 |
| Total Liabilities | 4.065 | 7.008 | 12.251 | 5.794 |
| Total Long Term Debt | 0 | 0 | 0 | 0 |
| Total Equity | 65.023 | 94.786 | 28.409 | 12.019 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 131.363 | 78.811 |
| Common Stock | 0.002 | 0.002 | 0 | 0 |
| Additional Paid-In Capital | 234.225 | 228.155 | 2.879 | 2.007 |
| Retained Earnings (Accumulated Deficit) | -169.188 | -133.367 | -105.836 | -68.799 |
| Unrealized Gain (Loss) | -0.016 | -0.004 | 0.003 | 0 |
| Total Liabilities & Shareholders’ Equity | 69.088 | 101.794 | 40.66 | 17.813 |
| Total Common Shares Outstanding | 21.3578 | 20.9793 | 19.1556 | 19.1556 |
| Other Liabilities, Total | 0.008 | 0.011 | ||
| Total Preferred Shares Outstanding | 0 | |||
| Laekumata arved, neto | 0.021 | |||
| Other Current Assets, Total | 1.353 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 58.222 | 67.078 | 74.496 | 76.051 | 88.821 |
| Raha ja lühiajalised investeeringud | 55.28 | 63.67 | 72.554 | 73.586 | 85.688 |
| Raha ja ekvivalendid | 8.36 | 13.364 | 11.452 | 7.864 | 10.589 |
| Lühiajalised investeeringud | 46.92 | 50.306 | 61.102 | 65.722 | 75.099 |
| Prepaid Expenses | 2.942 | 3.408 | 1.942 | 2.465 | 3.133 |
| Total Assets | 60.586 | 69.088 | 76.638 | 82.821 | 90.852 |
| Property/Plant/Equipment, Total - Net | 2.335 | 1.981 | 2.113 | 2.006 | 2.002 |
| Other Long Term Assets, Total | 0.029 | 0.029 | 0.029 | 0.136 | 0.029 |
| Total Current Liabilities | 4.228 | 4.057 | 4.49 | 4.141 | 6.278 |
| Accounts Payable | 0.541 | 0.527 | 2.066 | 2.101 | 1.956 |
| Accrued Expenses | 2.216 | 2.582 | 1.729 | 1.543 | 3.378 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 1.471 | 0.948 | 0.695 | 0.497 | 0.944 |
| Total Liabilities | 4.33 | 4.065 | 4.502 | 4.154 | 6.29 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.102 | 0.008 | 0.012 | 0.013 | 0.012 |
| Total Equity | 56.256 | 65.023 | 72.136 | 78.667 | 84.562 |
| Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
| Additional Paid-In Capital | 235.767 | 234.225 | 232.641 | 231.183 | 229.376 |
| Retained Earnings (Accumulated Deficit) | -179.337 | -169.188 | -160.513 | -152.524 | -144.816 |
| Unrealized Gain (Loss) | -0.176 | -0.016 | 0.006 | 0.006 | 0 |
| Total Liabilities & Shareholders’ Equity | 60.586 | 69.088 | 76.638 | 82.821 | 90.852 |
| Total Common Shares Outstanding | 21.3578 | 21.3578 | 21.3166 | 21.2847 | 21.0559 |
| Long Term Investments | 4.628 | ||||
| Preferred Stock - Non Redeemable, Net | 0 | 0 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Netotulu/algväärtus | -35.821 | -27.531 | -37.037 | -28.378 |
| Raha majandustegevusest | -31.5 | -32.064 | -31.215 | -28.216 |
| Raha majandustegevusest | 0.519 | 0.395 | 0.303 | 0.175 |
| Mittelikviidsed varad | 5.433 | -0.369 | 0.598 | 0.366 |
| Muutused tööjõus | -1.631 | -4.559 | 4.921 | -0.379 |
| Tulu investeeringutelt | 10.751 | -42.56 | -20.62 | -1.461 |
| Kapitalikulutused | -0.488 | -1.023 | -0.605 | -1.461 |
| Muud rahavood investeeringutelt, kokku | 11.239 | -41.537 | -20.015 | 0 |
| Rahavood investeeringutelt | 0.695 | 92.172 | 54.871 | 42.019 |
| Rahavoogudesse investeerimine | 0 | -4.16 | -0.045 | 0 |
| Aktsiate emiteerimine (tagasiost), neto | 0.695 | 96.332 | 54.916 | 42.019 |
| Rahaline kogumuutus | -20.054 | 17.548 | 3.036 | 12.342 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -10.149 | -35.821 | -27.146 | -19.157 | -11.449 |
| Cash From Operating Activities | -6.524 | -31.5 | -22.545 | -17.045 | -9.264 |
| Cash From Operating Activities | 0.122 | 0.519 | 0.383 | 0.247 | 0.118 |
| Non-Cash Items | 3.81 | 5.433 | 3.946 | 2.508 | 1.169 |
| Changes in Working Capital | -0.307 | -1.631 | 0.272 | -0.643 | 0.898 |
| Cash From Investing Activities | 1.52 | 10.751 | -0.035 | -9.096 | -13.657 |
| Capital Expenditures | 0 | -0.488 | -0.484 | -0.304 | -0.136 |
| Other Investing Cash Flow Items, Total | 1.52 | 11.239 | 0.449 | -8.792 | -13.521 |
| Cash From Financing Activities | 0 | 0.695 | 0.614 | 0.587 | 0.092 |
| Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
| Issuance (Retirement) of Stock, Net | 0 | 0.695 | 0.614 | 0.587 | 0.092 |
| Net Change in Cash | -5.004 | -20.054 | -21.966 | -25.554 | -22.829 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| Deerfield Management Company, L.P. | Hedge Fund | 6.8373 | 377265 | 0 | 2022-12-31 | MED |
| OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 5.3895 | 297380 | -2 | 2023-03-22 | LOW |
| BML Capital Management LLC | Investment Advisor | 1.6 | 88282 | 0 | 2022-12-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.5436 | 29995 | 13 | 2022-12-31 | LOW |
| Guerard (Frederic) | Individual Investor | 0.4451 | 24562 | 16153 | 2023-03-03 | HIGH |
| CVF 2018, LLC | Corporation | 0.3531 | 19485 | -56817 | 2021-12-31 | |
| First Manhattan Co. LLC | Investment Advisor | 0.3512 | 19381 | -1476 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.2019 | 11143 | -3178 | 2022-12-31 | HIGH |
| Breuil (Robert S) | Individual Investor | 0.1861 | 10266 | 5360 | 2023-03-14 | HIGH |
| Zamiri (Parisa) | Individual Investor | 0.1495 | 8247 | 5554 | 2023-03-03 | HIGH |
| BNY Mellon Asset Management | Investment Advisor | 0.1297 | 7159 | -54 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.0857 | 4730 | -12 | 2022-12-31 | LOW |
| Johnson & Johnson Innovation-JJDC, Inc. | Venture Capital | 0.0641 | 3539 | 0 | 2022-12-31 | LOW |
| Susquehanna International Group, LLP | Investment Advisor | 0.0581 | 3204 | -1313 | 2022-12-31 | MED |
| Hatteras Venture Partners | Venture Capital | 0.0557 | 3076 | -111584 | 2021-12-31 | LOW |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.0542 | 2993 | -1578 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.0454 | 2505 | 0 | 2022-12-31 | LOW |
| Advisor Group, Inc | Investment Advisor | 0.0246 | 1357 | 0 | 2022-12-31 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.0208 | 1150 | 0 | 2022-12-31 | LOW |
| Morgan Stanley & Co. LLC | Research Firm | 0.0154 | 851 | 0 | 2022-12-31 | MED |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
Graybug Vision, Inc. Company profile
Ettevõttest Graybug Vision, Inc.
Graybug Vision, Inc. on kliinilise faasi biofarmatseutiline ettevõte, mis keskendub uuenduslike ravimite väljatöötamisele võrkkesta ja nägemisnärvi haiguste raviks. Ettevõtte peamine tootekandidaat GB-102 on võrkkesta haigusi põhjustava neovaskulaarse kasvu ja läbilaskvuse inhibiitori sunitiniibi mikroosakeste depotvormulatsiooni intravitreaalne süstimine. Ettevõte arendab GB-102 intravitreaalse süstena, mida manustatakse üks kord kuus kuud aastas vanusega seotud märja makulaarse degeneratsiooni (AMD) ja diabeetilise makulaödeemi (DME) raviks. Samuti kasutab ta oma tehnoloogiaid GB-103, GB-102 üks kord aastas manustatava preparaadi väljatöötamiseks diabeetilise retinopaatia (DR) raviks, ning GB-401, mis on intravitreaalselt süstitav depotvorm, mis sisaldab beeta-adrenoblokaatorite eelravimit, mille annustamisskeem on üks kord kuue kuu tagant või kauem, primaarse avatud nurga glaukoomi (POAG) raviks.
| Industry: | Bio Therapeutic Drugs |
505 Coast Boulevard South
Suite 307
LA JOLLA
CALIFORNIA 92037
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com